Related Experiment Videos
[Homocysteine--CRP--lipoprotein (a). When do you evaluate the "new" risk factors]
1Medizinischen Klinik II, Klinikum Grosshadern der LMU München. parhofer@med2.med.uni-muenchen.de
Insights
Homocysteine, inflammatory markers, hemostatic factors, and lipoprotein(a) are linked to atherosclerosis. Interventional studies are lacking to prove causality, suggesting targeted testing and intervention for specific patient groups.
Area of Science:
- Cardiovascular Medicine
- Atherosclerosis Research
- Biomarker Analysis
Context:
- Established independent risk factors for atherosclerotic disease include homocysteine, inflammatory markers (e.g., C-reactive protein), hemostatic factors (fibrinogen, PAI-1, factor VII, factor VIII), and lipoprotein(a).
- The precise relationship between these factors and atherosclerosis (causal versus marker) remains unclear.
- Limited interventional studies exist to demonstrate the benefits of correcting these specific risk factors.
Purpose:
- To evaluate the clinical utility and indications for testing specific atherosclerotic risk factors.
- To guide the appropriate use of interventions based on biomarker levels.
- To clarify the role of homocysteine, fibrinogen, and lipoprotein(a) in risk assessment and management.
Summary:
- Testing for homocysteine, fibrinogen, and lipoprotein(a) should be reserved for specific clinical scenarios.
- These scenarios include patients with existing atherosclerosis, a family history of premature disease without traditional risk factors, or uncertainty regarding primary prevention needs.
- Elevated levels of these markers warrant consideration of early intervention with lipid-lowering drugs or aspirin, with homocysteine correction being an exceptional measure.
Impact:
- Provides guidance on the selective testing of key atherosclerotic risk factors, optimizing resource allocation.
- Supports evidence-based clinical decision-making for primary and secondary prevention of atherosclerotic disease.
- Highlights the need for further interventional research to establish causal links and therapeutic benefits.
Abstract:
Homocysteine, inflammatory markers (e.g. CRP), hemostatic factors (fibrinogen, PAI-1, factor VII and factor VIII) and lipoprotein (a) are independent risk factors for atherosclerotic disease. Although the association between these factors and atherosclerosis is clear, it is uncertain whether this signals a causal relationship, or whether the parameters simply represent markers of atherosclerosis. Currently, there are no reports on interventional studies demonstrating a benefit from correcting these risk factors. The determination of homocysteine, fibrinogen and lipoprotein should therefore be restricted to certain situations, such as atherosclerosis or a family history of the disease without classical risk factors, or uncertainty about the need for primary pharmacological prevention. An increase in these parameters should prompt the early use of lipid-lowering drugs or aspirin. In exceptional cases only (homocysteine), correction of the risk factors should be considered.